Rare diseases
Investigational molecules
Locations
364 conditions with trials, the busiest first
1 206 trials across Europe, recruiting first
Study of MK-1045 plus rituximab in patients with newly diagnosed follicular lymphoma
FranceRituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia
The NetherlandsEfficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial
AustriaPhase 3 Study of Orelabrutinib with Rituximab and Bendamustine vs. Rituximab and Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma Patients
CzechiaEvaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A
AustriaA Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors
AustriaSafety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs
SpainStudy of nivolumab plus drug combination versus standard first-line therapy in patients with advanced Hodgkin lymphoma
PolandStudy of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive
AustriaStudy of MK-1045 alone or with tocilizumab in patients with Non‑Hodgkin Lymphoma to evaluate safety and efficacy
FranceCemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
FranceDoxycycline for Asymptomatic Anal LGV Infection in Patients with Asymptomatic Anal LGV Infection
FranceThe therapies tested most often in Blood and lymphatic system disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
